Advertisement
Advertisement
MOLN
Molecular Partners AG - ADR
3.16
USDSponsored
0.00
0.00%
Nov 10, 15:59 UTC -5
Closed
After-Market
3.32
+0.16
+5.10%
Molecular Partners AG - ADR (MOLN) Earnings
MOLN Earnings Reports
Positive Surprise Ratio
MOLN beat 4 of 4 last estimates.
100%
Next Report
Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Molecular Partners AG - ADR earnings per share and revenue
On Aug 25, 2026, MOLN reported earnings of -0.35 USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -0.45% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Molecular Partners AG - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Molecular Partners AG - ADR reported EPS of -$0.35, missing estimates by --, and revenue of $0.00, -- -- expectations.
How did the market react to Molecular Partners AG - ADR's Q2 2026 earnings?
The stock price moved down -0.45%, changed from $4.40 before the earnings release to $4.38 the day after.
When is Molecular Partners AG - ADR expected to report next?
The next earning report is scheduled for Mar 10, 2027.
What are the forecasts for Molecular Partners AG - ADR's next earnings report?
Based on --
analysts, Molecular Partners AG - ADR is expected to report EPS of -- and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.